

Navinci reports record sales growth of 72% in 2025

Uppsala, Sweden – March 24, 2026 — Navinci today reported its 2025 annual results. Sales revenue increased by 72%, while operating expenses remained stable, marking a significant step toward the company’s long-term goals.

Navinci is a Swedish life science tools company with proprietary technology that helps researchers identify proteins, protein–protein interactions, and post-translational modifications with exceptional precision. The technology provides scientists deeper insight into how cells function in their natural environment, supporting a better understanding of diseases and how drugs work.

The company is experiencing strong momentum with sales increasing 72% to SEK 18.1m in 2025. Adjusting for currency effects, the growth was even stronger at 86%. The growth trend was consistent among all major geographical regions, with Asia displaying particularly high growth.

Cost of goods sold was negatively impacted by one-off expenses related to the disposal of materials exceeding their best-before date. Other expenses remained largely stable compared to 2024 levels. In aggregate, earnings before interest and taxes (EBIT) improved to SEK -37.4m in 2025.

“Last year’s increase in sales revenue is a testament to the strength of our technology and the value it delivers to customers. I’m very pleased with the progress we’re seeing. Alongside the positive sales trend, 2025 was a pivotal year in which we established a new management team and developed a five-year strategy that positions us in the best possible way for the future.” said Jenny Sundqvist, CEO Navinci.

Key figures for 2025 in SEKm (2024 in brackets)

- Sales revenue: 18.1 (10.5)
- Cost of goods sold: 4.7 (2.0)
- Gross profit: 13.5 (8.8)
- Operating expenses: -49.2 (48.6)
- EBIT: -37.4 (-41.4)



For further information, please contact:

Magnus Hurst, CFO
E-mail: magnus.hurst@navinci.se

Jenny Sundqvist, CEO
E-mail: jenny.sundqvist@navinci.se

Jenny Sundqvist will attend the LSX World Congress Europe, in Lisbon, 25-26 March.

About Navinci

Navinci is a Swedish biotech company specializing in developing innovative solutions for studying *in situ* protein expression and interactions. With a focus and a strong legacy in developing *in situ* proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth. Learn more at www.navinci.se